Basics |
Geron Corporation
Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.
|
IPO Date: |
July 31, 1996 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$802.52M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.11 | 2.89%
|
Avg Daily Range (30 D): |
$0.05 | 3.20%
|
Avg Daily Range (90 D): |
$0.05 | 3.64%
|
Institutional Daily Volume |
Avg Daily Volume: |
2.76M |
Avg Daily Volume (30 D): |
7.81M |
Avg Daily Volume (90 D): |
10.18M |
Trade Size |
Avg Trade Size (Sh.): |
343 |
Avg Trade Size (Sh.) (30 D): |
491 |
Avg Trade Size (Sh.) (90 D): |
511 |
Institutional Trades |
Total Inst.Trades: |
2,640 |
Avg Inst. Trade: |
$1.87M |
Avg Inst. Trade (30 D): |
$1.27M |
Avg Inst. Trade (90 D): |
$1.37M |
Avg Inst. Trade Volume: |
.61M |
Avg Inst. Trades (Per Day): |
2 |
Market Closing Trades |
Avg Closing Trade: |
$2.36M |
Avg Closing Trade (30 D): |
$1.25M |
Avg Closing Trade (90 D): |
$1.43M |
Avg Closing Volume: |
812.4K |
|
|
Financials |
|
TTM |
Q1 2025 |
Q4 2024 |
Basic EPS
|
$-.21
|
$-.03
|
$-.04
|
Diluted EPS
|
$-.21
|
$-.03
|
$-.04
|
Revenue
|
$ 116.29M
|
$ 39.6M
|
$ 47.54M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -139.02M
|
$ -19.84M
|
$ -25.35M
|
Operating Income / Loss
|
$ -134.3M
|
$ -16.7M
|
$ -20.05M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -105.26M
|
$ 4.73M
|
$ 18.71M
|
PE Ratio
|
|
|
|
|
|
|